One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That’s because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results. Thus, these stocks, especially when trading at low prices, have the potential to rapidly increase in value. In such cases, a frenzy can quickly spike the stock, leading to a relatively short-term situation ...